These results suggested that the epigenetic inhibition of SMAD4 expression by DNA methylation in poor-prognosis HCC may contribute to the loss of the tumor-suppressive arm of the canonical TGFβ pathway, as is documented in regard to other tumors, including pancreatic and colorectal carcinoma [31,32]. The gene discussed is SMAD4; the disease is hepatocellular carcinoma.